
R2810-ONC-1676
NCT03257267
JCP030
An Open-Label, Randomized, Phase 3 Clinical Trial Of REGN2810 Versus Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Carcinoma
Status:
Closed to Accrual

III
Phase

2nd+
Line of Therapy

Advanced / Metastatic
Disease Stage

Biomarker(s)
N/A
Investigational
Product
Cemiplimab (REGN2810)
Human programmed death receptor -1 (PD-1) monoclonal antibody (i.v.)
Treatment Arms
o Experimental: Experimental Therapy
o Active Comparator: Control Therapy